Octapharma strengthens its innovation strategy with a USD 11.75 million Series A investment in Abram Scientific

• Octapharma leads a USD 11.75 million Series A investment in Abram Scientific, marking its first major move into diagnostics.

• The funding advances CoagCare™, a portable coagulation platform delivering results in under 10 minutes.

• The investment supports Octapharma’s strategy to expand innovation beyond therapies and strengthen its position in critical care.

Octapharma announces that it is leading a USD 11.75 million Series A investment in a US-based medical device company, Abram Scientific. This marks the first time the company has taken a lead role in an external healthcare venture.

The funding will support the development of a next-generation portable coagulation diagnostic platform intended for use in trauma, surgery, and critical care. The investment reflects Octapharma’s intention to broaden access to individualised coagulation management therapies, including innovation in point-of-care diagnostics.

Executive statement

“This investment represents an important milestone for Octapharma. We view innovation as extending beyond the development of our own therapies. Supporting transformative technologies that complement and strengthen patient care is a natural evolution of our long-term strategy.”

“Abram Scientific’s CoagCare™ platform aligns strongly with our commitment to advancing critical care and coagulation management. By contributing capital, expertise, and a strategic partnership, we aim to help accelerate meaningful innovation that ultimately improves outcomes for patients worldwide,” says Tobias Marguerre, Deputy Chairman.

“The critical care market in the United States continues to grow rapidly, driven by an increasing focus on rapid, reliable diagnostics that directly impact patient outcomes,” says Flemming Nielsen, President, Octapharma USA, Inc. “Investors are recognising the need for technologies that deliver actionable information when every minute matters. Our investment in Abram Scientific underscores Octapharma’s belief in the potential of point-of-care coagulation diagnostics to transform care pathways and improve critical care delivery.”

Oliver Hegener, Global Senior Vice President, IBU Critical Care, emphasises that CoagCare™ “stands out because of its ability to deliver a comprehensive coagulation profile faster, more easily, and in a portable format.” He adds that these advantages have the potential to overcome the most important barriers to routine use, making it both a strong strategic complement to Octapharma’s Critical Care portfolio and a strategic area for investment.

For full details, see Abram Scientific’s official announcement below.